Inflectra/Remsima (Germany) Wave 3 is the third in a series of syndicated reports designed to track physician perception and uptake of Hospira’s Inflectra and Mundipharma’s Remsima, two different brands of Celltrion’s infliximab biosimilar CT-P13. Unlike previous reports in this series, this report also tracks Biogen’s Benepali, the only etanercept biosimilar to launch in the EU to date.
We surveyed rheumatologists and gastroenterologists in Germany to determine their level of awareness of and experience and satisfaction with Inflectra, Remsima, and Benepali in order to identify key drivers and barriers to these biosimilars’ uptake and to gauge physicians’ level of contact with marketers of Inflectra, Remsima, Remicade, and Benepali.
Questions Answered in This Report:
Since Wave 1 was fielded one year ago, how have awareness and perceptions of infliximab biosimilars changed among rheumatologists and gastroenterologists in Germany, and how do their awareness and perceptions of Benepali compare with those of Inflectra/Remsima at three months’ postlaunch?
Among German rheumatologists and gastroenterologists, what are the key drivers of the uptake of Inflectra/Remsima and Benepali, and what proportion of patients are switched to these agents from Remicade or Enbrel?
What proportion of German rheumatologists and gastroenterologists have been actively encouraged to use Inflectra/Remsima or Benepali or to meet a prescribing quota for these biosimilars?
What benefit would another biosimilar need to offer for German rheumatologists and gastroenterologists to preferentially prescribe it in place of Inflectra/Remsima or Benepali?